The FDA-cleared device failed its main test in the largest trial yet

STUDY: Loo SK et al, Research Square

STUDY TYPE: Randomized controlled trial

FUNDING: National Institute of Mental Health

Background

The FDA cleared the Monarch trigeminal nerve stimulation (TNS) device for ADHD in children aged 7 to 12 in 2019. The device stimulates the trigeminal nerve overnight with mild electrical current. A small trial supported it, but a larger one did not. Now, a new large trial brings mixed results.

The Study
  • 219 medication-free children with moderate to severe ADHD were randomized; 211 completed.
  • Children used active stimulation (120 Hz) or a low-frequency control (2 Hz) nightly for 4 weeks.
  • Primary outcome = clinician-rated ADHD scale (ADHD-RS); Secondary = Clinical Global Impression of Improvement (CGI-I).

The Monarch System

Results

There was no significant difference on the primary outcome, the one that counts: 26% drop in symptoms with treatment vs 22% with placebo). Parent ratings (SNAP-IV) also showed no difference.

The CGI-I, however, showed improvement: 35% of the active group were much improved or better, versus 15% of controls (odds ratio 3.07; number needed to treat 5).

The inconsistency is puzzling. With twice as many responders, each improving by about half, we’d expect symptom scores to separate too.

Side Effects

None.

Limitations
  • Preprint, not yet peer reviewed
  • The primary outcome failed
  • The claim that the 2-Hz control is partly active is post hoc (data fishing), and its 15% response rate matched an inert sham in the earlier trial
  • Only 4 weeks long
Practice Implications
  1. TNS failed in its two large trials, but remains FDA cleared, which is a lower bar to pass than approval.
  2. That said, the approval bar has lowered a lot in the past two years.

—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report

What’s Your Take? Share in Comments

Leave a Reply

Your email address will not be published. Required fields are marked *